Wegovy prescriptions in the US grow for another week
Although Novo Nordisk’s obesity treatment grew less than in prior weeks, one bank still detects the presence of strong underlying demand.
by marketwire, translated by daniel pedersen
[fakta1]
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Demand for Novo Nordisk's Wegovy accelerating
For subscribers
Blockbuster weight-loss drug Wegovy to be available on NHS
For subscribers
